Spots Global Cancer Trial Database for ondansetron
Every month we try and update this database with for ondansetron cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients | NCT04503668 | Gynecologic Can... | Ondansetron Dexamethasone Neurokinin-1 Re... Olanzapine Compazine | 18 Years - 89 Years | University of Michigan Rogel Cancer Center | |
| Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV) | NCT02473042 | Post-Operative ... Breast Cancer | Electrical Stim... Zofran Dexamethasone Phenergan Pepcid Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | NCT00324467 | Lymphoma, Non-H... Advanced Stage ... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Ondansetron Dexamethasone Diphenhydramine Acetaminophen Ifosfamide Mesna (IV) Mesna (oral) Carboplatin Etoposide Rituximab Ondansetron Dexamethasone Diphenhydramine Acetaminophen PET Scan | 18 Years - | British Columbia Cancer Agency | |
| A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. | NCT00601172 | Nausea and Vomi... | Casopitant Dexamethasone Placebo Ondansetron | 18 Years - | GlaxoSmithKline | |
| Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer | NCT00020657 | Nausea and Vomi... Unspecified Adu... | dolasetron mesy... granisetron hyd... ondansetron prochlorperazin... quality-of-life... | 18 Years - 120 Years | University of Rochester | |
| Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) | NCT01640340 | Malignant Neopl... | aprepitant palonosetron hy... ondansetron dexamethasone | 18 Years - 88 Years | Ohio State University Comprehensive Cancer Center | |
| Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy | NCT00169572 | Nausea and Vomi... Chemotherapy-In... | Aprepitant Ondansetron GW679769 Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide | NCT02991456 | Chemo-radiation... | Rolapitant Ondansetron | 18 Years - | Duke University | |
| Heart Safety Study of Ondansetron in Children Receiving Chemotherapy | NCT01896440 | Malignant Child... | Ondansetron | 6 Months - 18 Years | University of Oklahoma | |
| Heart Safety Study of Ondansetron in Children Receiving Chemotherapy | NCT01896440 | Malignant Child... | Ondansetron | 6 Months - 18 Years | University of Oklahoma | |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | NCT01450826 | Nausea Vomiting Glioma | aprepitant ondansetron | 18 Years - | Duke University | |
| Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting | NCT00971399 | Radiotherapy In... | ramosetron ondansetron | 20 Years - | Seoul National University Hospital | |
| Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone | NCT05872893 | Pediatric Cance... | Ondansetron Dexamethasone | - 18 Years | Immune Oncology Research Institute | |
| Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) | NCT01640340 | Malignant Neopl... | aprepitant palonosetron hy... ondansetron dexamethasone | 18 Years - 88 Years | Ohio State University Comprehensive Cancer Center | |
| Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV) | NCT02473042 | Post-Operative ... Breast Cancer | Electrical Stim... Zofran Dexamethasone Phenergan Pepcid Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen | NCT00016380 | Cancer | dexamethasone ondansetron quality-of-life... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting | NCT01031498 | Acute Myelogeno... Chemotherapy-in... | Ondansetron Palonosetron | 18 Years - | M.D. Anderson Cancer Center | |
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer. | NCT03606369 | Breast Neoplasm Antineoplastic ... Antiemetics Quality of Life | Palonosetron Ondansetron | 18 Years - | Instituto Nacional de Cancerologia de Mexico | |
| Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy | NCT02732015 | Locally Advance... | Dexamethasone Doxorubicin Fosaprepitant D... Ifosfamide Laboratory Biom... Mesna Ondansetron Questionnaire A... Rolapitant Hydr... Vincristine Sul... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy | NCT00891761 | Cancer Chemotherapy-In... Nausea and Vomi... Solid Tumor Can... | Dexamethasone Dexamethasone IV casopitant (... IV casopitant (... Ondansetron | 18 Years - | GlaxoSmithKline | |
| Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy | NCT00169572 | Nausea and Vomi... Chemotherapy-In... | Aprepitant Ondansetron GW679769 Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) | NCT01640340 | Malignant Neopl... | aprepitant palonosetron hy... ondansetron dexamethasone | 18 Years - 88 Years | Ohio State University Comprehensive Cancer Center | |
| A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. | NCT00601172 | Nausea and Vomi... | Casopitant Dexamethasone Placebo Ondansetron | 18 Years - | GlaxoSmithKline | |
| Preoperative Oral Dexamethasone to Improve Recovery After Surgery | NCT02234466 | Breast Cancer | Oral dexamethas... Ondansetron Gelatin capsule | 18 Years - 80 Years | University of Manitoba | |
| Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer | NCT00020657 | Nausea and Vomi... Unspecified Adu... | dolasetron mesy... granisetron hyd... ondansetron prochlorperazin... quality-of-life... | 18 Years - 120 Years | University of Rochester | |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | NCT01450826 | Nausea Vomiting Glioma | aprepitant ondansetron | 18 Years - | Duke University | |
| Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients | NCT04503668 | Gynecologic Can... | Ondansetron Dexamethasone Neurokinin-1 Re... Olanzapine Compazine | 18 Years - 89 Years | University of Michigan Rogel Cancer Center | |
| Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | NCT00871910 | Solid Tumors Lymphoma, Non-H... Multiple Myelom... | SCH 727965 SCH 727965 SCH 727965 SCH 727965 Aprepitant Ondansetron Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. | NCT00601172 | Nausea and Vomi... | Casopitant Dexamethasone Placebo Ondansetron | 18 Years - | GlaxoSmithKline | |
| Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation | NCT01536392 | Cancer of the C... | Granisetron Ondansetron Questionnaires Study Drug Diar... | 18 Years - | M.D. Anderson Cancer Center | |
| Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors | NCT00609765 | Pancreatic Canc... | Avastin Fluorouracil Doxorubicin Streptozocin Dexamethasone Ondansetron | 18 Years - 80 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen | NCT00016380 | Cancer | dexamethasone ondansetron quality-of-life... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation | NCT01536392 | Cancer of the C... | Granisetron Ondansetron Questionnaires Study Drug Diar... | 18 Years - | M.D. Anderson Cancer Center | |
| Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting | NCT00971399 | Radiotherapy In... | ramosetron ondansetron | 20 Years - | Seoul National University Hospital | |
| A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) | NCT01636947 | Nausea Vomiting | Aprepitant Aprepitant Plac... Ondansetron Dexamethasone Ondansetron Pla... Rescue Therapy ... | 21 Years - | Merck Sharp & Dohme LLC | |
| Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone | NCT01536691 | Cancer Malignancy | ramosetron ondansetron | 20 Years - | Hallym University Medical Center | |
| Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | NCT00954941 | Hematologic Dis... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Ondansetron Aprepitant | 18 Years - | M.D. Anderson Cancer Center | |
| Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients | NCT04503668 | Gynecologic Can... | Ondansetron Dexamethasone Neurokinin-1 Re... Olanzapine Compazine | 18 Years - 89 Years | University of Michigan Rogel Cancer Center | |
| Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy | NCT00005994 | Nausea and Vomi... Unspecified Adu... | ondansetron | 18 Years - | University of Rochester | |
| A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. | NCT00601172 | Nausea and Vomi... | Casopitant Dexamethasone Placebo Ondansetron | 18 Years - | GlaxoSmithKline | |
| A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy | NCT00891761 | Cancer Chemotherapy-In... Nausea and Vomi... Solid Tumor Can... | Dexamethasone Dexamethasone IV casopitant (... IV casopitant (... Ondansetron | 18 Years - | GlaxoSmithKline | |
| Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | NCT00324467 | Lymphoma, Non-H... Advanced Stage ... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Ondansetron Dexamethasone Diphenhydramine Acetaminophen Ifosfamide Mesna (IV) Mesna (oral) Carboplatin Etoposide Rituximab Ondansetron Dexamethasone Diphenhydramine Acetaminophen PET Scan | 18 Years - | British Columbia Cancer Agency |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
